EMERYVILLE, Calif., Nov. 23, 2021 /PRNewswire/ — Amyris, Inc. (Nasdaq: AMRS) (“Amyris”), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-Market™ operating platform, today announced that management will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on Wednesday, December 1st at 3:30 pm ET.
A live webcast of the presentation and a replay will be available on the Investor Relations section of the company’s website at https://investors.amyris.com/events-and-presentations.
About Amyris
Amyris (Nasdaq: AMRS) is a leading synthetic biotechnology company, transitioning the Clean Health & Beauty and Flavors & Fragrances markets to sustainable ingredients through fermentation and the company’s proprietary Lab-to-Market™ operating platform. This Amyris platform leverages state-of-the-art machine learning, robotics and artificial intelligence, enabling the company to rapidly bring new innovation to market at commercial scale. Amyris ingredients are included in over 20,000 products from the world’s top brands, reaching more than 300 million consumers. Amyris also owns and operates a family of consumer brands that is constantly evolving to meet the growing demand for sustainable, effective and accessible products.
Amyris, the Amyris logo and Lab-to-Market are trademarks or registered trademarks of Amyris, Inc. in the U.S. and/or other countries.
View original content to download multimedia:https://www.prnewswire.com/news-releases/amyris-to-present-at-the-evercore-isi-4th-annual-healthconx-conference-on-december-1-2021-301431144.html
SOURCE Amyris, Inc.
TAIPEI, Dec. 15, 2025 /PRNewswire/ -- Meridian Innovation's Cheetah thermal imaging sensor claimed this year's Best…
New White Paper Details the Dual-System Architecture Behind AISIR for Radar™ and How Atomathic Closes…
CMS compliance deadlines and heightened cybersecurity expectations are accelerating payer interoperability and utilization management modernization…
Collaboration to focus on building a leading, US-based biotech dedicated to addressing underserved patients impacted…
WASHINGTON, D.C. / ACCESS Newswire / December 15, 2025 / Leading national organizations have come…
We remain on track to deliver year-over-year revenue growth and to generate positive adjusted EBITDA…